Foghorn Therapeutics Inc.

NASDAQ: FHTX · Real-Time Price · USD
5.02
-0.13 (-2.43%)
At close: Aug 15, 2025, 3:59 PM
5.07
1.00%
After-hours: Aug 15, 2025, 05:10 PM EDT

Foghorn Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
22.6M 34.16M 19.23M 1.32M
Cost of Revenue
3.12M 109.69M 19.23K 7.51M
Gross Profit
22.6M -75.53M 19.21M -6.2M
Operating Income
-102.68M -107.91M -117.14M -100.73M
Interest Income
11.9M 10.88M 5.67M 59K
Pretax Income
-86.62M -94.2M -108.88M -101.32M
Net Income
-86.62M -98.43M -108.87M -103.23M
Selling & General & Admin
28.36M 32.37M 30.75M 21.73M
Research & Development
94.53M 109.69M 105.62M 80.33M
Other Expenses
2.4M n/a n/a 2.49M
Operating Expenses
125.28M 142.06M 136.37M 102.05M
Interest Expense
n/a n/a n/a 1.91M
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
125.28M 142.06M 136.37M 102.05M
Income Tax Expense
n/a 4.23M -8.26K 1.91M
Shares Outstanding (Basic)
54.9M 41.97M 41.59M 37.17M
Shares Outstanding (Diluted)
54.9M 41.97M 41.59M 37.17M
EPS (Basic)
-1.58 -2.34 -2.62 -2.78
EPS (Diluted)
-1.58 -2.34 -2.62 -2.78
EBITDA
-97.17M -104.45M -113.82M -96.19M
EBIT
-100.28M -107.91M -117.14M -99.41M
Depreciation & Amortization
3.12M 3.45M 7.9M 7.51M